Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ruppert

Showing results (81-90 of 188) with videos related to

Pageof 19
Sort By:
Leukemia & Lymphoma|April 4, 2013
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101Jeffrey A Jones, Amy S Ruppert, Weiqiang Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2013
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridolJia Ji, Diane R Mould, Kristie A Blum, et al.
Haematologica|January 25, 2012
Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approachDeborah M Stephens, Amy S Ruppert, Kristie Blum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2011
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712Jennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.
Pediatrics|November 5, 1999
American Academy of Pediatrics. Committee on Children with Disabilities. The treatment of neurologically impaired children using patterningP R Ziring, D brazdziunas, W C Cooley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 24, 2019
Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell TransplantationHassan Issa, Nidhi Sharma, Qiuhong Zhao, et al.
Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society|June 15, 2021
Poly(lactide-co-ε-caprolactone) scaffold promotes equivalent tissue integration and supports skin grafts compared to a predicate collagen scaffoldDavid S Ruppert, Mahmoud M Mohammed, Mohamed M Ibrahim, et al.
Clinical Proteomics|September 1, 2015
Proteomic profiling identifies specific histone species associated with leukemic and cancer cellsRajbir Singh, Sean W Harshman, Amy S Ruppert, et al.
Blood|April 2, 2020
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPIAmy S Ruppert, Jesse G Dixon, Gilles Salles, et al.
Bone Marrow Transplantation|July 29, 2014
The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myelomaS M Jaglowski, A S Ruppert, C C Hofmeister, et al.
Pageof 19

Showing results (81-90 of 188) with videos related to

Sort By:
Pageof 19
Leukemia & Lymphoma|April 4, 2013
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101Jeffrey A Jones, Amy S Ruppert, Weiqiang Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2013
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridolJia Ji, Diane R Mould, Kristie A Blum, et al.
Haematologica|January 25, 2012
Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approachDeborah M Stephens, Amy S Ruppert, Kristie Blum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2011
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712Jennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.
Pediatrics|November 5, 1999
American Academy of Pediatrics. Committee on Children with Disabilities. The treatment of neurologically impaired children using patterningP R Ziring, D brazdziunas, W C Cooley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 24, 2019
Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell TransplantationHassan Issa, Nidhi Sharma, Qiuhong Zhao, et al.
Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society|June 15, 2021
Poly(lactide-co-ε-caprolactone) scaffold promotes equivalent tissue integration and supports skin grafts compared to a predicate collagen scaffoldDavid S Ruppert, Mahmoud M Mohammed, Mohamed M Ibrahim, et al.
Clinical Proteomics|September 1, 2015
Proteomic profiling identifies specific histone species associated with leukemic and cancer cellsRajbir Singh, Sean W Harshman, Amy S Ruppert, et al.
Blood|April 2, 2020
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPIAmy S Ruppert, Jesse G Dixon, Gilles Salles, et al.
Bone Marrow Transplantation|July 29, 2014
The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myelomaS M Jaglowski, A S Ruppert, C C Hofmeister, et al.
Pageof 19